Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAYNASDAQ:DRTSOTCMKTS:RDGLNASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsWay$10.74-6.0%$9.52$5.67▼$12.00$206.01M1.3266,586 shs28,615 shsDRTSAlpha Tau Medical$3.06-0.3%$2.79$1.75▼$4.39$215.37M0.9950,132 shs10,749 shsRDGLVivos$0.12-2.9%$0.12$0.06▼$0.26$54.15M1.06895,928 shs394,769 shsSGHTSight Sciences$4.15-1.5%$3.20$2.03▼$8.45$212.99M2.46215,374 shs59,131 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsWay-2.64%+10.77%+16.41%+11.85%+83.01%DRTSAlpha Tau Medical0.00%+5.32%+11.23%+15.85%+32.33%RDGLVivos-2.93%-8.15%-11.56%-5.76%-32.81%SGHTSight Sciences+0.48%+0.24%+23.10%+54.78%-38.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsWay2.9758 of 5 stars3.53.00.00.01.90.81.9DRTSAlpha Tau Medical2.9419 of 5 stars3.55.00.00.02.71.70.0RDGLVivos0.3187 of 5 stars0.05.00.00.00.00.80.0SGHTSight Sciences1.4183 of 5 stars1.14.00.00.02.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsWay 3.00Buy$14.2532.68% UpsideDRTSAlpha Tau Medical 3.00Buy$8.00161.44% UpsideRDGLVivos 0.00N/AN/AN/ASGHTSight Sciences 2.29Hold$4.02-3.10% DownsideCurrent Analyst Ratings BreakdownLatest RDGL, DRTS, BWAY, and SGHT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025BWAYBrainsWayHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.004/29/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/9/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/17/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsWay$43.46M4.67N/AN/A$2.50 per share4.30DRTSAlpha Tau MedicalN/AN/AN/AN/A$1.21 per shareN/ARDGLVivos$20K2,707.47N/AN/A($0.02) per share-5.97SGHTSight Sciences$78.11M2.74N/AN/A$2.47 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsWay-$4.20M$0.20109.1167.13N/A3.88%3.52%2.26%8/5/2025 (Estimated)DRTSAlpha Tau Medical-$29.16M-$0.46N/AN/AN/AN/A-38.62%-29.89%8/13/2025 (Estimated)RDGLVivos-$2.89M-$0.01N/A∞N/AN/AN/A-197.34%8/11/2025 (Estimated)SGHTSight Sciences-$55.55M-$0.98N/AN/AN/A-63.30%-47.28%-32.72%7/30/2025 (Estimated)Latest RDGL, DRTS, BWAY, and SGHT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025DRTSAlpha Tau Medical-$0.14-$0.12+$0.02-$0.12$0.03 millionN/A5/13/2025Q1 2025BWAYBrainsWay$0.02$0.04+$0.02$0.04$11.45 million$11.54 million5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainsWayN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/ARDGLVivosN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainsWayN/A4.524.23DRTSAlpha Tau Medical0.0810.99N/ARDGLVivosN/A25.4825.48SGHTSight Sciences0.3610.189.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsWay30.11%DRTSAlpha Tau Medical2.65%RDGLVivosN/ASGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipBWAYBrainsWay19.00%DRTSAlpha Tau Medical39.50%RDGLVivos18.50%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsWay12018.88 million15.24 millionNot OptionableDRTSAlpha Tau Medical8070.38 million42.30 millionNo DataRDGLVivos1453.51 million369.81 millionNot OptionableSGHTSight Sciences21051.70 million36.09 millionOptionableRDGL, DRTS, BWAY, and SGHT HeadlinesRecent News About These CompaniesMillennium Management LLC Invests $464,000 in Sight Sciences, Inc. (NASDAQ:SGHT)June 10 at 3:12 AM | marketbeat.comsight sciences appoints new board member and holds annual meetingJune 7, 2025 | uk.investing.comSquarepoint Ops LLC Buys 128,355 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)June 4, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of "Hold" from AnalystsMay 31, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Shares Sold by Bank of America Corp DEMay 30, 2025 | marketbeat.comBNP Paribas Financial Markets Invests $262,000 in Sight Sciences, Inc. (NASDAQ:SGHT)May 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Acquires 88,738 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 25, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Sells 135,268 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 21, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Shares Purchased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comProsight Management LP Acquires 377,625 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)May 17, 2025 | marketbeat.comSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27thMay 14, 2025 | globenewswire.comBrokers Set Expectations for Sight Sciences Q1 EarningsMay 13, 2025 | marketbeat.comSight Sciences stock holds as Needham reiterates ratingMay 11, 2025 | uk.investing.comSight Sciences, Inc. (SGHT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comSight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue GuidanceMay 10, 2025 | finance.yahoo.comSight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 8, 2025 | zacks.comSight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comWhy Sight Sciences, Inc.’s (SGHT) Stock Is Down 5.02%April 26, 2025 | aaii.comSight Sciences appoints new board memberApril 24, 2025 | investing.comSight Sciences, Inc. to Report First Quarter Financial Results on May 8, 2025April 24, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRDGL, DRTS, BWAY, and SGHT Company DescriptionsBrainsWay NASDAQ:BWAY$10.74 -0.68 (-5.95%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Alpha Tau Medical NASDAQ:DRTS$3.06 -0.01 (-0.33%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Vivos OTCMKTS:RDGL$0.12 0.00 (-2.93%) As of 06/12/2025 03:59 PM EasternVivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.Sight Sciences NASDAQ:SGHT$4.14 -0.07 (-1.54%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
